In reply
We appreciate Spielmans and colleagues' interest in our article; however, their concerns about the data in our article are unfounded.
Spielmans and colleagues state that study LYAQ included atomoxetine as a treatment and should have been excluded. In fact, the first 2 active treatment visits did not include atomoxetine and our analysis of the data from this study was restricted to this period (days 1-42 postbaseline depending on the subject). Furthermore, although patients in this study had comorbidities including attention-deficit/hyperactivity disorder, the majority (81%) of patients had a depressive disorder. As such, our inclusion of this study was scientifically appropriate.